Press Room

News / Nov 10, 2021

World Science Day 2021

Science saves lives - to celebrate science is to celebrate life



Today we celebrate World Science Day for Peace and Development.

A year ago, on a day like this, Covid-19 limited our day-to-day life and narrowed humanity's expectations like never before. When would partial or total confinement end? When would the rules that restrained the most basic human instinct – close contact with other people, come to an end?

A month later, in December 2020, anticipating the best expectations by years… science has found not one but several vaccines able to stop the spread of the virus. Hovione closely witnessed this extraordinary evolution.

Today, on World Science Day, our scientists spread across three continents, feel especially proud to be part of the international scientific community that will always live up to its responsibilities.

World health can count on us.

Science saves lives — to celebrate science is to celebrate life.











 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026